<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198779</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01</org_study_id>
    <nct_id>NCT04198779</nct_id>
  </id_info>
  <brief_title>Interest of the Smartphone Application &quot;MonCœur&quot; in the Follow-up of Patients With Heart Failure</brief_title>
  <acronym>APPLIMONCOEUR</acronym>
  <official_title>Interest of the Smartphone Application &quot;MonCœur&quot; in the Follow-up of Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a chronic disease that requires careful monitoring and therapeutic
      education. Smartphones have made their appearance in patients lives and allow close contact
      with them. The possibility of using a digital application dedicated to patients with heart
      failure concerning the symptoms to be monitored, treatments, diet, appointments, physical
      activity could improve the monitoring and the prognosis of patients following their
      hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to demonstrate that the use of a special application dedicated to
      the monitoring of heart failures disease has a favorable impact on the occurrence of
      readmissions and, ultimately, cardiovascular mortality. The aim of this study is also to
      demonstrate that the use of this &quot;MonCœur&quot; application improves symptoms, quality of life,
      treatment compliance, diet compliance, and physical activity in patient with heart failure
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">August 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicentric, randomized, controlled, open, 2 parallel arms study, in 11 centers.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on the impact of patient health self-care</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms of the score of the European Heart Failure Self-care Behaviour Scale, consisting of 9 items each evaluated on a 5-point Likert scale, and allowing the calculation of a standardized global score from 0 to 100: the highest score indicating better &quot;self-care&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on hospitalisation rate</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms on the number of days without hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on cardiovascular parameters</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms of Brain Natriuretic Peptid (nanograms / liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on patient compliance</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms on percentage of appointments scheduled versus appointments honored. Comparison between the 2 study arms of the score of the treatment observance scale Ameli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on patient quality of life: Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms of the score of the Minnesota Living with Heart Failure Questionnaire. It provides a total score (range 0-105, from best to worst), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the use of &quot;MonCoeur&quot; application on patient physical activity</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Comparison between the 2 study arms of the score of the Qappa (&quot;questionnaire d'activité physique pour personnes âgées&quot; / translation in english: &quot;physical activity questionnaire for seniors&quot;) physical activity questionnaire. The QAPPA uses the calculation system of the volume of physical activity per minute and per week and classified as high, moderate, or low level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe how often and how the application is used by patients</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Calculation of the number and type of parameters filled in the application.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Decompensation</condition>
  <arm_group>
    <arm_group_label>APPLI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Care support with implementation of the application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional care support</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APPLI</intervention_name>
    <description>The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.</description>
    <arm_group_label>APPLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient hospitalized for acute or decompensated heart failure

          -  Patient with a smartphone and able to use a digital application

          -  Beneficiary of a social protection scheme

          -  Patients benefiting from a telemedicine program can be included

        Exclusion Criteria:

          -  Acute coronary syndrome during ongoing hospitalization.

          -  Acute myocarditis, constrictive pericarditis, acute endocarditis during ongoing
             hospitalization.

          -  Isolated right heart failure of respiratory origin.

          -  Existence of a cause considered rapidly reversible to acute heart failure:
             tachyarrhythmia, excessive bradycardia, acute anemia, acute renal failure, malignant
             hypertension, overdose or cardiotoxic drug intoxication.

          -  Indication of cardiac surgery scheduled within 3 months after hospitalization,
             patients with Tavi or MItraclip expected within 3 months

          -  Extracardiac disease with short-term prognosis (progressive neoplasia).

          -  Refusal or incapacitation of language or psychic to sign informed consent

          -  Patients participating in an other biomedical research can not participate in this
             study for the first 6 months, not to interfere with the consultation process of the
             study.

          -  Pregnant or lactating women can't participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle BERTHELOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bicêtre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle BERTHELOT, MD</last_name>
    <phone>+33 1 45 21 3735</phone>
    <email>emmanuelle.berthelot@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tessa BERGOT</last_name>
    <phone>+33 1 44 90 70 33</phone>
    <email>tessa.bergot@sfcardio.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine JOBBE-DUVAL, MD</last_name>
      <phone>+33 4 72 11 88 80</phone>
      <email>ajobbeduval@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibaud DAMY, MD</last_name>
      <phone>+33 1 49 81 22 53</phone>
      <email>thibaud.damy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel SALVAT, MD</last_name>
      <phone>+33 4 76 76 76 95</phone>
      <email>MSalvat@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BERTHELOT, MD</last_name>
      <phone>+33145213735</phone>
      <email>emmanuelle.berthelot@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal De Groote, MD</last_name>
      <phone>+33 3 20 44 57 21</phone>
      <email>pascal.degroote@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien LOGEAT, MD</last_name>
      <phone>+33 1 49 95 82 33</phone>
      <email>damien.logeart@lrb.aphp-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert HAGEGE, MD</last_name>
      <phone>+ 33 1 56 09 37 13</phone>
      <email>albert.hagege@aphp.ff</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire BOULETI, MD</last_name>
      <phone>+33 6 32 67 14 29</phone>
      <email>claire.bouleti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de ROUEN - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice BAUER, MD</last_name>
      <phone>+33 2 32 88 54 06</phone>
      <email>fabrice.bauer@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérald ROULE, MD</last_name>
      <phone>+33 3 69 55 05 85</phone>
      <email>jose.roule-gerald@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Musse de Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Michel TARTIERE, MD</last_name>
      <phone>+33 4 94 14 59 31</phone>
      <email>Jean-Michel.Tartiere@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier LAIREZ, MD</last_name>
      <phone>+33 5 61 32 28 73</phone>
      <email>lairez.o@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

